Tesamorelin (5mg)
GHRH analogue: visceral fat research
1.500.000 ₫
Delivery method:
Single vial
1.500.000 ₫
Tesamorelin pen
1.950.000 ₫
Tesamorelin is a 44-amino-acid GHRH analog specifically researched for visceral adipose tissue (VAT) reduction. The branded medicine Egrifta is FDA-approved for excess abdominal fat in adults with HIV-associated lipodystrophy; this approval does not apply to VCP research products. In phase-3 trials, daily Tesamorelin reduced VAT by ~15–18% over 26 weeks versus placebo, with concurrent reduction in liver fat and no adverse effect on fasting glucose. It works by stimulating natural pulsatile GH release from the pituitary — preserving negative feedback — while preferentially mobilising deep abdominal fat rather than subcutaneous fat. The primary component of the Cutting stack (paired with Ipamorelin). Dosed nightly via SubQ injection. Typically run in 12–26 week cycles. Available as 5mg, 10mg and 20mg vials. Prohibited in sport by WADA at all times.
Dosage
Start 1mg nightly; after 1 week double to 2mg nightly (2mg/day is the licensed trial dose)
Duration of effect
Daily dosing; benefits build over weeks (plasma half-life: ~26-38 minutes)
See full half-life table →Key Features
- Targets visceral belly fat specifically
- Preserves lean muscle mass
- Improves lipid profile & triglycerides
- Natural pulsatile GH release
- No impact on blood glucose levels
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection once daily, at night. Store refrigerated.
Research Highlights
- Visceral fat fell 15.2% versus a 5.0% rise on placebo over 26 weeks (Falutz 2007, 412 participants)
- Reduction concentrated in deep abdominal fat, with little change in subcutaneous fat
- No significant change in fasting glucose in the phase 3 trials
- Visceral fat tends to return after stopping
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Obesity & Weight Management in HIV — Curr HIV/AIDS Rep (PMC, 2026)
Clinical Research
Tesamorelin reduced visceral adipose tissue by 15% while preserving lean muscle mass.
Read full studyAdditional Research
Source: Falutz et al., New England Journal of Medicine (2007)
Phase 3 randomised placebo-controlled trial in HIV-associated lipodystrophy: Tesamorelin produced a 15% reduction in visceral adipose tissue at 26 weeks without affecting subcutaneous fat — establishing the GHRH-analogue's selective visceral fat-loss profile.
Read full studyHuman Clinical Trials
- Tesamorelin in HIV lipodystrophyNew England Journal of Medicine · 2007
412 patients: visceral (deep abdominal) fat fell 15.2% on tesamorelin while rising 5.0% on placebo.
Read the trial412participants